Patent intelligence · US
US 2021038684
Compositions and Methods for Cancer Immunotherapy
Compositions and Methods for Cancer Immunotherapy
Patent details — US 2021038684
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 11, 2021
- Expiration
- Feb 6, 2041
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- CPC classes
- A61K 9/ 00 A I, A61K 38/ 16 A I, A61K 39/ 395 A I, A61K/3816
Quick answer
US 2021038684 (Compositions and Methods for Cancer Immunotherapy) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Feb 11, 2021. Expires Feb 6, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 38/ 16 A I, A61K 39/ 395 A I, A61K/3816, A61K/381793, A61K/382013
More from ALKERMES PHARMA IRELAND LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
US 2023302008
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
granted -
WO 2023156493
FORMES CRISTALLINES DE NALTREXONE
granted -
WO 2023154894
COMPOSITIONS ET PROCÉDÉS D'IMMUNOTHÉRAPIE ANTICANCÉREUSE
granted -
CY 2022006
ΠΡΟΦΑΡΜΑΚΑ ΦΟΥΜΑΡΙΚΩΝ ΑΛΑΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΑΓΩΓΗ ΠΟΙΚΙΛΩΝ ΝΟΣΩΝ
granted -
US 2022354866
IMMEDIATE RELEASE MULTILAYER TABLET
granted -
CA 3172871
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted -
CA 3172874
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted
Frequently asked questions
What is US patent 2021038684?
US 2021038684 (Compositions and Methods for Cancer Immunotherapy) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Feb 11, 2021. Expires Feb 6, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2021038684?
ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2021038684 expire?
Our index shows an expiration date of Feb 6, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.